Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
We report the concentrations of maraviroc in the cerebrospinal fluid (CSF) and plasma of six HIV-1-infected patients with both neurological impairment and detectable HIV-1 replication in CSF. One month after starting maraviroc, the viral load in the CSF decreased significantly (P = 0.005). The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC90) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173).
Melica
Giovanna
G
Department of Clinical Immunology, Henri Mondor Hospital, Université Paris XII Creteil, Creteil, France. giovanna.melica@hmn.aphp.fr
Canestri
Ana
A
Peytavin
Gilles
G
Lelievre
Jean D
JD
Bouvier-Alias
Magali
M
Clavel
Cyril
C
Calvez
Vincent
V
Lascaux
Anne S
AS
Katlama
Christine
C
Levy
Yves
Y
D000328:Adult; D019380:Anti-HIV Agents; D002493:Central Nervous System Diseases / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000821:virology; D003510:Cyclohexanes / Q000493:pharmacokinetics*; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D014230:Triazoles / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc